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Pasireotide for the Medical Management of Feline
Hypersomatotropism
C.J. Scudder, R. Gostelow, Y. Forcada, H.A. Schmid, D. Church, and S.J.M. Niessen
Background: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor
ligand somatostatin analog that improves biochemical control of humans with HST.
Hypothesis/Objectives: Pasireotide improves biochemical control of HST and diabetes mellitus in cats.
Animals: Hypersomatotropism was diagnosed in diabetic cats with serum insulin-like growth factor-1 (IGF-1) concentra-
tion >1,000 ng/mL by radioimmunoassay and pituitary enlargement.
Methods: Insulin-like growth factor 1 was measured and glycemic control assessed using a 12-hour blood glucose curve
on days 1 and 5. On days 2, 3, and 4, cats received 0.03 mg/kg pasireotide SC q12h. IGF-1, insulin dose, and estimated insu-
lin sensitivity (product of the area under the blood glucose curve [BGC] and insulin dose) were compared pre- and post treat-
ment. Paired t-tests or Wilcoxon signed rank tests were employed for comparison where appropriate; a linear mixed model
was created to compare BGC results.
Results: Insulin-like growth factor 1 decreased in all 12 cats that completed the study (median [range] day 1: 2,000 ng/mL
[1,051–2,000] and day 5: 1,105 ng/mL [380–1,727], P = .002, Wilcoxon signed rank test). Insulin dose was lower on day 5
than on day 1 (mean reduction 1.3 [0–2.7] units/kg/injection, P = .003, paired t-test). The product of insulin dose and area
under the BGC was lower on day 5 than day 1 (difference of means: 1,912; SD, 1523; u 9 mg/dL 9 hours, P = .001; paired
t-test). No clinically relevant adverse effects were encountered.
Conclusions: Short-acting pasireotide rapidly decreased IGF-1 in cats with HST and insulin-dependent diabetes. The
decrease in IGF-1 was associated with increased insulin sensitivity.
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Spontaneously occurring feline hypersomatotropism(HST) is caused by a functional growth hormone
(GH)-secreting pituitary somatotrophinoma. Prevalence
studies estimate 1 in 3 to 1 in 5 diabetic cats have HST-
induced diabetes mellitus.1,a,b The hypersomatropic
state induces insulin resistance, arthropathy, general
abdominal organomegaly, and cardiovascular disease.2–4
These conditions impair the health of affected cats. Dia-
betic cats affected by HST often are difficult to control
with exogenous insulin alone, and glycemic control will
not manage all aspects of the disease.5
Several different treatment options are available for
humans with HST including hypophysectomy, radiother-
apy, and medical treatment. Medical treatment of exces-
sive GH secretion consists of use of dopamine agonists,
growth hormone receptor antagonists, and somatostatin
analogs, with the latter being the drug of choice in most
patients.6 Five somatostatin receptors subtypes (SSTR 1
to 5) have been reported in humans, and all subtypes are
present in human somatotrophinomas but expression lev-
els vary.7 Members of the somatostatin analog family
bind with differing affinity to these receptor subtypes,
and binding affinity variability could explain the different
growth hormone lowering efficacy of each analog.8
No previous report has documented successful clinical
management of HST in cats by medical inhibition of
pituitary GH secretion.3 Use of the dopamine agonist,
L-selegiline, which is a selective irreversible monoamine
oxidase-B inhibitor, did not result in clinical improve-
ment.9 Intravenously administered octreotide decreases
serum GH concentration in a minority of affected cats,
but clinical effects were not reported.10 These results
raise questions, such as: do somatotrophinomas in cats
express somatostatin receptors consistently or is the
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configuration of their SSTRs different from those found
in somatotrophinomas of humans?
A recent advancement in the medical treatment of
HST in humans is the use of a novel somatostatin
analog, pasireotide.c Pasireotide has 30-, 5-, and 39-fold
higher binding affinity for SSTR1, 3, and 5, respec-
tively, compared with octreotide.11–13 Pasireotide
decreases GH release in some octreotide-resistant soma-
totrophinomas in humans and resulted in better GH
control in a clinical trial in humans as compared with
octreotide.14
We hypothesized that somatotrophinomas in cats
would be amenable to medical inhibition when treated
with a somatostatin analog that has high binding affin-
ity at several SSTRs, thereby also providing indirect
evidence of SSRT expression by these tumors in cats.
We specifically aimed to assess if sc administration of a
short-acting pasireotide preparation q12h would
improve biochemical control of HST in cats and
improve control of their diabetes mellitus. Our second-
ary goal was to document the tolerability of the short-
acting pasireotide preparation in cats with HST.
Materials and Methods
Animals
The clinical trial was approved by the Ethics and Welfare Com-
mittee at the RVC (Royal Veterinary College ethical approval ref-
erence number: URN 2011 1120). Cats were prospectively enrolled
from December 2011 to December 2013. Enrolled cats had a diag-
nosis of HST based on a history of diabetes mellitus, serum IGF-1
concentration > 1000 ng/mL and pituitary enlargement diagnosed
using computed tomography. Written informed consent was
obtained from owners of enrolled cats. All cats had a CBC, serum
biochemistry, urinalysis, and abdominal ultrasound examination
performed before enrollment. Patients were excluded if they had a
disease that was considered to be more critical to the cat’s welfare
than the consequences of HST.
Serum IGF-1 concentration was measured at a commercial lab-
oratoryd using a radioimmunoassay validated for cats.15 The upper
limit of IGF-1 concentration quantitation was 2,000 ng/mL, and
any result above this value was recorded as 2,000 ng/mL. Pituitary
contrast-enhanced computed tomography was performed as previ-
ously described and a pituitary dorsoventral height, measured by a
board-certified radiologist, > 4 mm was considered to be enlarge-
ment.16
Treatment Protocol
All treatments were carried out at the Queen Mother Hospital
for Animals (QMHA), RVC. Enrolled cats were hospitalized for
at least 5 consecutive days. All cats were fed the same food as nor-
mally provided by their owners at home. All cats had a period of
at least 12 hours of acclimatization to their hospital environment
before beginning the study. On day 1, all cats received the same
insulin regimen as prescribed before enrollment in the study. A 12-
hours blood glucose curve (BGC) was performed using a glucome-
ter validated for use in catse every 2 hours from the time of morn-
ing insulin administration to the time of evening insulin
administration. Blood was collected for measurement of pretreat-
ment serum IGF-1 concentration. On days 2, 3, and 4, cats
received 0.03 mg/kg of a short-acting pasireotide preparation SC
q12h (the dosage was extrapolated from a dosage proven to be
effective and safe in human patients).17 Glycemic control monitor-
ing and insulin dosage on days 2, 3, and 4 were determined by the
attending clinician to adjust the insulin dose to the individual cat’s
need, but the insulin type was not changed. At the minimum,
blood glucose concentration was measured each day at the time of
insulin injection. Cats did not receive any insulin if the blood glu-
cose concentration at time of injection was < 126 mg/dL. If the
blood glucose concentration was > 126 mg/dL, a sliding scale was
used to guide the clinician in his or her choice of insulin dose. If
the blood glucose concentration was > 250 mg/dL, the original
insulin dose given at time of enrollment was used. Incremental
decreases in insulin dose were made if blood glucose concentration
was between 180 and 250 mg/dL or between 126 and 180 mg/dL.
The magnitude of the decrease was left to the discretion of the
attending clinician, given the known interindividual variation in
insulin sensitivity and exogenous insulin response in diabetic ani-
mals. However, clinicians were clearly instructed to avoid hypogly-
cemia at all times and to decrease the most recently administered
insulin dose by 50% should hypoglycemia be identified. On day 5,
cats had a second 12-hour BGC performed and a blood sample
was collected for a second measurement of serum IGF-1 concen-
tration.
Monitoring for adverse drug reactions consisted of several daily
physical examinations, inspection of the pasireotide injection site
during interactions not associated with physical examination by
the nursing staff and clinicians such as blood glucose monitoring,
‘over-the-door’ monitoring, grooming and general husbandry dur-
ing hospitalization. Written records of the amount of food eaten
by each cat, urination and defecation behavior including fecal con-
sistency, any unusual patient behavior and intermittent measure-
ments of blood glucose concentration were recorded. The
frequency of glycemic monitoring was increased if any cat had a
blood glucose concentration < 145 mg/dL. A cat was fed addi-
tional quantities of its food and put under more frequent monitor-
ing, if blood glucose concentration was < 72 mg/dL and the cat
was asymptomatic for hypoglycemia.
Statistical Analysis
Data were analyzed using a spreadsheet and commercially avail-
able statistical software.f,g A P value < 0.05 was considered signifi-
cant. Data were analyzed for normal distribution visually using
histograms and by performing Shapiro–Wilk tests. Nonparametric
data are presented as median and range and parametric data as
mean and standard deviation (SD). Wilcoxon signed rank tests
were performed to compare paired nonparametric data, paired t-
tests for paired parametric data; a Pearson’s correlation test was
performed when comparing the correlation between the change in
IGF-1 concentration on day 1 and day 5 and pituitary height. A
linear mixed model was created to compare BGC determined on
days 1 and 5. The area under the BGC was multiplied by the
exogenous insulin dose, as a surrogate measure of insulin sensitiv-
ity, and to compare the insulin sensitivity on days 1 and 5.
Results
Twenty two cats were excluded from enrollment;
owners of 14 cats elected hypophysectomy, 7 cats were
not included because owners declined to participate and
1 cat was not included, because it had a temperament
unsuited for the required trial procedures. Thirteen cats
were enrolled in the study.
Twelve cats completed the 5-day study period. The
cat that did not complete the study was lethargic before
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inclusion. This cat had experienced 2 episodes of tonic-
clonic seizure activity on day 4, experienced grade 3
International Renal Interest Society acute kidney injury
(serum creatinine concentration on day 3 was 1.43 mg/
dL and on day 5 was 2.53 mg/dL) and the owners
elected for the cat to be euthanized on day 5. The cat
subsequently underwent postmortem examination. Pitui-
tary histopathology identified an acidophilic adenoma
of the pars distalis, consistent with a somatotrophino-
ma, which had 5 mitotic figures per 10 high-powered
fields. The hypothalamus and thalamus overlying the
pituitary mass were compressed and had focal extensive
malacia.
The remaining 12 cats had significantly lower serum
IGF-1 concentrations on day 5 compared with day 1
(median [range] day 1: 2,000 ng/mL [1,051–2,000] and
day 5: 1,105 ng/mL [380–1,727], P = .002, related sam-
ples Wilcoxon signed rank test); Fig 1A. The mean
decrease in serum IGF-1 concentration was 698 ng/mL
(SD, 320) and the decrease in serum IGF-1 concentra-
tion was significantly correlated with pituitary height
(r = 0.69, P = .013, Pearson’s correlation test). The
mean insulin decrease between days 1 and 5 was 1.3
units/kg/injection, Fig 1B. Blood glucose curves per-
formed on days 1 and 5 were not significantly different,
having a mean blood glucose concentration on days 1
and 5 of 278 mg/dL (SD, 78 mg/dL) and 260 mg/dL
(SD, 78 mg/dL), respectively. The products of the insu-
lin dose and area under BGC for all 12 cats were signif-
icantly lower on day 5 than day 1 (difference 1,912; SD,
1,523, u 9 mg/dL 9 hours, P = .001, paired t-test),
consistent with increased insulin sensitivity (Fig 1C).
Three cats experienced small intestinal diarrhea, hav-
ing voluminous soft stools that did not resolve during
the study period. One of these 3 cats also experienced
moderate abdominal enlargement suspected to be
caused by gaseous small intestinal distention, which
waxed and waned during the study period. Treatments
were not administered to manage these clinical signs
because appetite and demeanor were not affected. Five
cats had nonsymptomatic hypoglycemia (blood glucose
concentration < 72 mg/dL), which resolved after provi-
sion of additional food and prompted a decrease in
insulin dosage at the time of next injection. No cat
experienced symptomatic hypoglycemia.
Discussion
Our study is the first to document effective medical
treatment for hypersomatotropism in cats. Pasireotide
was well tolerated and decreased serum IGF-1 concen-
trations in all cats. The decrease in IGF-1 was likely
> 698 ng/mL, because 7/12 cats that completed the
study had a serum IGF-1 concentrations > 2000 ng/mL
at enrollment. In addition, insulin sensitivity improved
in almost all cats, despite the short treatment time.
We chose to use IGF-1 as a biomarker of GH rather
than measure GH directly. This decision was made for
several reasons. A validated radioimmunoassay for
feline GH is described, but was unavailable at the time
of the study.18 Serum GH concentrations can vary as a
A
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Fig 1. (A) Scatter plot representing the change in serum IGF-1
concentrations of 12 diabetic acromegalic cats that completed a
pasireotide drug trial receiving 0.03 mg/kg q12h of a short-acting
pasireotide compound SC on days 2, 3, and 4. (B) Scatter plot rep-
resenting the change in insulin dose on days 1 and 5 of 12 diabetic
acromegalic cats that completed a pasireotide drug trial receiving
0.03 mg/kg q12h of a short-acting pasireotide compound SC on
days 2, 3, and 4. (C) Scatter plot representing the change in the
product of insulin dose per injection and total area under the 12-
hour blood glucose curve (BGC) of 12 diabetic acromegalic cats
that completed a pasireotide drug trial receiving 0.03 mg/kg q12h
of a short-acting pasireotide compound SC on days 2, 3, and 4.
(u 9 mg/dL 9 hours) = insulin units 9 area under BGC.
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result of pulsatile release from the pituitary gland, and
dynamic growth hormone tests have not been validated
in the cat. The half-life of GH in humans is 13.8 to
14.2 minutes, whereas IGF-1 bound to IGF-1 binding
protein 3 has a half-life of 15.7 to 21 hours.19
Insulin-like growth factor 1 therefore represents an
average GH concentration over a longer period of time.
Finally, serum IGF-1 concentration has been shown to
be a useful marker of GH activity in the cat and in
humans with acromegaly.18
Measuring serum IGF-1 concentrations on days 1 and
5 was considered sufficient to identify a clinically relevant
change in average blood GH concentration based on
IGF-1 half-life in humans, despite a lack of studies to
determine the half-life of feline IGF-1. A longer study
period may have allowed more marked changes in IGF-1
concentrations to be identified if IGF-1 in cats has a
longer half-life than IGF-1 in humans. We performed a
serum biochemical profile at entry to the study, because
liver and kidney disease can cause increased serum IGF-1
concentrations in humans and if a similar effect occurs in
cats, it could have contributed to a misdiagnosis of
HST.20 None of the enrolled cats had evidence of
impaired liver or kidney function on these blood tests.
We closely monitored food intake during the study
because short-term fasting can decrease serum IGF-1
concentration in cats.21 Fortunately, none of the cats in
the study experienced noticeable decrease in caloric
intake during hospitalization.
The area under the BGC was multiplied by the exog-
enous insulin dose given as a surrogate measure of insu-
lin sensitivity and to compare insulin sensitivity on days
1 and 5. This calculated parameter was used based on
the physiological principle that in a diabetic animal with
a set insulin sensitivity, a decrease in exogenous insulin
would lead to a worsening hyperglycemia (and vice
versa). If such worsening hyperglycemia is not observed,
the insulin sensitivity must have changed. Although this
indicator has not been previously evaluated in the cat,
it seems more appropriate than reporting only the exog-
enous insulin dose or area under the BGC because both
are intrinsically related. In addition, the use of this sur-
rogate marker was deemed more appropriate for this
study, given that the more commonly accepted mea-
sures of insulin sensitivity (e.g., hyperinsulinemic clamp,
minimal model analysis of the frequently sampled glu-
cose tolerance test), would have been more invasive and
likely would not have provided additional clinically use-
ful information.22,23
Somatrophinomas in humans predominantly express
SSTR1, 2 and 5. These receptors have been pharmaco-
logical targets in the management of acromegaly in
humans.24,25 Pasireotide exhibits high affinity binding to
SSTR1, 2, 3, and 5 unlike octreotide which preferen-
tially binds to SSTR2.26 Previous attempts to use octre-
otide in cats to control GH release and improve
glycemic control have been unrewarding. Our results
suggest that this lack of effect may be because SSRT1
or SSRT5 activation is required to more effectively inhi-
bit GH release in feline somatotrophinomas and to
achieve a clinically relevant effect.
Eleven of the 12 cats that completed the trial were
given a lower dose of insulin on day 5 than on day 1 in
an attempt to avoid hypoglycemia. The lack of blinding
may have been a source of bias and led to a greater
inclination toward insulin dose reduction, despite the
provided guidelines. There is also an inherent weakness
of using BGCs as a diagnostic tool to assess diabetic
control considering the day-to-day variability in results
from these curves and altered level of activity of hospi-
talized cats compared with those in a home environ-
ment.27 Nevertheless, the area under these curves did
not change significantly from days 1 to 5 despite
decreases in the exogenous insulin dose, implying truly
increased insulin sensitivity.
Stress hyperglycemia is a commonly recognized phe-
nomenon in cats presented to veterinary practices.28,29
Hospitalization could either have contributed to pro-
gressively increasing levels of stress because of
repeated procedures such as blood sampling. Alterna-
tively, hospitalization also could have allowed acclima-
tization and decreased patient stress. It is impossible
to establish the exact influence of these factors in this
study, but it seems unlikely that decreased insulin
needs encountered in the treated cats were simply a
reflection of decreased stress hyperglycemia or coinci-
dence. Diabetic cats with HST have a type of diabetes
that usually requires high dosages of insulin.1 In addi-
tion, all cats had diabetes mellitus-related clinical signs
(e.g., polyuria, polydipsia) before the start of the
study. This finding suggests the insulin dose adminis-
tered before enrollment actually was still insufficient
to control their disease and the blood glucose concen-
trations recorded on day 1 were truly representative
and not a result of stress hyperglycemia alone. Use of
appropriate statistical methodology should further
have decreased the impact of random interday vari-
ability in BGCs on the study’s conclusions.
Most humans diagnosed with acromegaly are nondiabet-
ic, and use of pasireotide induces mild hyperglycemia in up
to 63% of these patients.14,30 Pasireotide-induced hypergly-
cemia in humans is not completely understood. It might be
explained by a decrease in the hypoglycemic effect of IGF-
1, and decreased incretin and insulin release.31 In rats, the
insulin/glucagon balance was identified as the most relevant
mechanism of pasireotide-induced hyperglycemia.32 The
physiology in the cat seems to be different. The insulin
resistance associated with excess GH secretion exerts a
more marked and dominant effect on insulin sensitivity in
cats compared with humans with HST. Therefore, decreas-
ing GH secretion and serum IGF-1 concentration improves
insulin sensitivity in the cat.
In addition to inhibiting pituitary hormone secretion,
somatostatin drugs have been shown to inhibit somato-
troph growth and induce apoptosis.33 Pasireotide inhib-
its vascular endothelial growth factor and vascular
endothelial proliferation in pituitary cell cultures within
48 hours of exposure, and is more potent than octreo-
tide at inhibiting vascular proliferation and pituitary
tumor growth in mice, rats, dogs, and humans.34–37
Whether pasireotide could induce a decrease in pituitary
tumor size in cats with HST remains to be determined,
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and long-term studies are indicated to investigate this
potential effect.
The cat that did not complete the trial showed pro-
gressive neurological deterioration and hypoglycemia
after 2 seizure episodes. This cat had the second largest
pituitary height in the study, and pituitary histopathol-
ogy identified a proliferative tumor with 5 mitotic fig-
ures per 10 high-powered fields. Pituitary neoplasms
with a high proliferation rate are associated with poorer
outcomes, and this cat had clinical signs of altered men-
tation before enrollment in the study.38 Postmortem
examination was consistent with an aggressive pituitary
neoplasm causing thalamic and hypothalamic compres-
sion. We believe the death of this cat is unlikely to be
related to pasireotide treatment but this possibility can-
not be excluded. Additional studies using pasireotide to
treat large pituitary masses or those that have a high
mitotic rate would be needed to determine the safety of
pasireotide in this patient subset.
Clinical signs that might be compatible with drug-
induced adverse effects were mild gastrointestinal distur-
bances in 3/12 cats. These adverse effects were similar
to those reported in octreotide and pasireotide trials in
human patients with acromegaly.39,40 Endogenous
somatostatin inhibits gastric emptying, gastric acid pro-
duction, and pancreatic, and biliary secretions. Admin-
istration of octreotide induces similar effects and
pasireotide also is likely to alter gastrointestinal physiol-
ogy.41 These effects would affect nutrient digestion and
absorption, explaining the encountered small intestinal
diarrhea and bloating. Studies performed over a longer
period of time using the short-acting pasireotide or a
long-acting pasireotide formulation are needed to deter-
mine the long term clinical tolerability of this drug in
cats, whether or not pasireotide increases the risk of
gastrointestinal upset, or if the observed signs were
coincidental.
A positive correlation was identified between the
decrease in serum IGF-1 concentration and pituitary
size. Tumor size and pretreatment serum IGF-1 concen-
tration were inversely correlated with likelihood of bio-
chemical control in humans diagnosed with acromegaly
and treated with somatostatins.42 Surgical debulking
has been used to improve biochemical control when
using somatostatin treatment, and has proven successful
even in patients that were previously poorly responsive
to somatostatin treatment.43 A clear explanation for
this difference in biochemical behavior in cats is not
available, and might lie in the fact that the behavior of
somatotrophinomas in cats still needs to be fully eluci-
dated. For example, different subsets of somatotrophi-
nomas in humans (densely granulated versus sparsely
granulated) respond differently to somatostatin analog
treatment.44
The duration of time a cat had been receiving insulin
treatment was not taken into account. A previous study
indicating that diabetic cats treated with insulin long
term have increased serum IGF-1 concentrations com-
pared with diabetic cats receiving insulin treatment over
shorter periods of time. Theoretically, this could lead to
a false increase in IGF-1 concentration and therefore
the false impression of the presence of HST.45 However
all included cats underwent intracranial imaging and
had convincing evidence of pituitary enlargement to
avoid inclusion of cats without HST. The inclusion of
cats with pituitary-dependent hyperadrenocortism,
which also could present with diabetes mellitus and
have similar computed tomography findings are also
unlikely because serum IGF-1 concentrations are
expected to be within normal limits or suppressed in
such patients.46 Finally, it would have been preferential
if IGF-1 concentrations > 2,000 ng/mL also had been
exactly quantified. Nevertheless, any negative conse-
quences of this omission would only have resulted in a
false impression that the drug was not effective in
decreasing IGF-1, which was not the case.
In conclusion, we identified consistently effective
medical management of HST in these cats. The novel
somatostatin analog pasireotide decreased circulating
IGF-1 and increased insulin sensitivity in confirmed
acromegalic cats. These results also suggest that most
somatotrophinomas in cats express somatostatin recep-
tors. All owners of cats that completed this short-act-
ing pasireotide compound trial opted to enroll their
cats in a long-acting pasireotide compound trial,
which was started immediately after completion of the
short-acting pasireotide trial. The results will be com-
municated separately on completion of the second
trial.
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